Combined inhibition of notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3200-3209

  Li, Ming ^a   Chen, Feng ^a,b   Clifton, Nicholas ^a   Sullivan, Daniel M ^a   Dalton, William S ^a   Gabrilovich, Dmitry I ^a   Nefedova, Yulia ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CYTOCHROME C; GAMMA SECRETASE INHIBITOR; NOTCH RECEPTOR; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN NOXA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION; XENOGRAFT;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-X PROTEIN; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; MICE; MULTIPLE MYELOMA; NITROPHENOLS; OLIGOPEPTIDES; PIPERAZINES; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650443207     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0372     Document Type: Article

References (37)

1. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: A new approach to the development of cell fate modifying agents. Oncogene 2003;22:6598-608.
2. Nefedova Y, Cheng P, Alsina M, Dalton W, Gabrilovich D. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004;103:3503-10.
3. Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004;103:3511-5.
4. Allman D, Punt J, Izon DJ, Aster JC, Pear WS. An invitation to T and more: Notch signaling in lymphopoiesis. Cell 2002;109:S1-S11. (Pubitemid 34457847)
5. Artavanis-Tsakonas S, Rand M, Lake R. Notch signaling: Cell fate control and signal integration in development. Science 1999;284: 770-6.
6. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008; 27:5124-31.
7. Nefedova Y, Gabrilovich D. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. Drug Resist Updat 2008;11:210-8.
8. Nefedova Y, Sullivan D, Bolick S, Dalton W, Gabrilovich D. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008;111:2220-9.
9. Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002;2:183-92.
10. Willis S, Fletcher J, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007;315:856-9.
11. Zha H, Reed J. Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol Chem 1997;272:31482-288.
12. Willis SN, Chen L, Dewson G, van Delft MF, Chen L, Czabotar PE, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005;19:1294-305.
13. Dai Y, Grant S. Targeting Multiple Arms of the Apoptotic Regulatory Machinery. Cancer Res 2007;67:2908-11.
14. Oltersdorf T, Elmore S, Shoemaker A, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81.
15. Cory S, Adams J. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 2005;8:5-6.
16. Trudel S, Stewart A, Li Z, Shu Y, Liang SB, Trieu Y, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007;13:621-9.
17. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007;26:2374-80.
18. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-88.
19. Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9:351.
20. Tahir S, Yang X, Anderson M, Morgan-Lappe SE, Sarthy AV, Chen J, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67:1176-83.
21. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-91.
22. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007;26:3972-9.
23. Gómez-Benito M, Marzo I, Anel A, Naval J. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. Mol Pharmacol 2005;67:1991-8.
24. Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005;175:4338-46.
25. Reynolds C, Maurer B. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med 2005;110:173-83.
26. Ong F, van Nieuwkoop J, de Groot-Swings G, Hermans J, Harvey MS, Kluin PM, et al. Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia 1995;9:1282-4.
27. Wuillème-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005;19:1248-52.
28. Le Gouill S, Podar K, Harousseau J, Anderson K. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 2004;3:1259-62.
29. Puthier D, Pellat-Deceunynck C, Barillé S, Robillard N, Rapp MJ, Juge-Morineau N, et al. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 1999;13:289-94.
30. Pettersson M, Jernberg-Wiklund H, Larsson L, Sundstrcom C, Givol I, Tsujimoto Y, et al. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 1992;79:495-502.
31. van Delft M, Wei A, Mason K, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-99.
32. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3- only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403.
33. Lee E, Czabotar P, van Delft MF, Michalak EM, Boyle MJ, Willis SN, et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol 2008;180:341-55.
34. Clementz A, Osipo C. Notch versus the proteasome: What is the target of gamma-secretase inhibitor-I? Breast Cancer Res 2009; 11:110-2.
35. Okumura K, Huang S, Sinicrope F. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res 2008;14: 8132-42.
36. Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008;112:2906-16.
37. Miller L, Goldstein N, Johannes W, Walton CH, Fujita M, Norris DA, et al. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol 2009;129:964-71.